Objective: Examine the clinical and biochemical features including serum intact PTH (iPTH) and plasma PTH-related peptide (PTHrP) levels in patients with malignancy-associated hypercalcemia (MAHC).
Material And Method: Forty-eight patients with histopathological or cytological proven malignancies and MAHC who were admitted to Siriraj Hospital were studied.
Results: The malignancies that caused MAHC were squamous cell carcinoma (45.8%), non-squamous cell solid tumors (31.3 %), and hematological malignancies (22.9%). Most patients (93.8%) had advanced stage malignancies. Corrected serum total calcium (cTCa) levels were 10.8-19.1 mg/dL (13.6 +/- 2.4) and severe hypercalcemia was observed in 17 cases (40.5%). Serum iPTH levels were 0.95-17.1 pg/mL (3.9 +/- 3.6). Most patients had suppressed serum iPTH levels of < 10 pg/mL. Plasma PTHrP levels were 0.2-44.0 pmol/L (3.8 +/- 6.8). There were 27 cases (56.3%) that had humoral hypercalcemia of malignancy (HHM) with plasma PTHrP levels of > 1.5 pmol/L, and 22 cases had squamous cell carcinoma. There was no difference in serum cTCa, phosphorus, alkaline phosphatase, and iPTH levels between patients with HHM and non-HHM. In 48 MAHC patients, serum cTCa correlated to plasma PTHrP (r = 0.35, p = 0.029) and to serum iPTH (r = 0.49, p = 0.003). In 25 patients with HHM, a stronger correlation between serum cTCa and serum iPTH (r = 0.55, p = 0.005) but not between serum cTCa and plasma PTHrP levels (r = 0.41, p = 0.05) was observed. Stepwise multiple regression analyses showed that serum iPTH but not plasma PTHrP levels independently correlated to serum cTCa levels (r = 0.39, p = 0.04).
Conclusion: The clinical manifestations of MAHC observed in the present study were similar to those previously reported. Serum calcium correlated to serum iPTH more strongly than to plasma PTHrP levels. The low but detectable serum iPTH level might play a role in the development of severe MAHC particularly in HHM.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients.
Int Urol Nephrol
December 2024
Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Background: Hyperphosphatemia is common in chronic kidney disease (CKD) patients, especially patients on hemodialysis. Tenapanor is a novel drug with fewer side effects and high compliance compared to traditional phosphate binders. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of tenapanor.
View Article and Find Full Text PDFSomatostatin Receptor Imaging in the Diagnosis and Management of Parathyroid Neuroendocrine Neoplasia.
Diagnostics (Basel)
December 2024
Almazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Background: Parathyroid tumors are classified as parathyroid neuroendocrine neoplasia (NEN) by the IARC-WHO classification. These tumors can occur with NENs from other sites, which often require total-body [68Ga]-DOTA-peptides PET/CT. This study aimed to assess the utility of [68Ga]-DOTA-peptide PET/CT in imaging parathyroid NENs and to evaluate the underlying mechanisms.
View Article and Find Full Text PDFTherapeutic effectiveness and safety profile of lanthanum carbonate in conjunction with calcium carbonate for managing hyperphosphatemia in hemodialysis patients: a meta-analysis of randomized controlled trials.
Am J Transl Res
November 2024
Department of Nephrology, Jiaxing Hospital of Traditional Chinese Medicine Jiaxing 314000, Zhejiang, China.
Objective: To comprehensively investigate the efficacy and safety of lanthanum carbonate in conjugation with calcium carbonate combination in hemodialysis patients with hyperphosphatemia via a meta-analysis of randomized controlled trials (RCTs).
Method: We conducted a literature search in databases of PubMed, Embase, and Web of Science for RCTs investigating the effect of lanthanum carbonate in combination with calcium carbonate for treating hyperphosphatemia in hemodialysis patients. The search covered all studies from the inception of the database until October 2023.
Prevalence of Vitamin D Deficiency and Its Association With Anthropometric and Hematological Parameters Among Infants at a Tertiary Care Center in Meerut, India: A Cross-Sectional Study.
Cureus
November 2024
Environmental Health and Epidemiology, Indian Council of Medical Research (ICMR) - National Institute for Research in Environmental Health, Bhopal, IND.
Introduction: Vitamin D is crucial in calcium homeostasis and bone metabolism, and its deficiency is widespread even in sun-rich regions like India. The present study sought to elucidate the prevalence of vitamin D deficiency in infants and its potential association with various anthropometric and hematological parameters.
Methods: The study was conducted in a tertiary care hospital in northern India (in 2013-14) and involved 77 nine-month-old infants.
Osteopenic Effect of Disulfiram Therapy in Patients With Alcohol Use Disorder.
Cureus
November 2024
Department of Endocrinology, Council of Scientific and Industrial Research-Central Drug Research Institute, Lucknow, IND.
Background: Disulfiram is widely used to treat alcohol use disorder. Alcohol per se adversely affects bone health. In the experimental study, disulfiram leads to apoptosis of osteoblast and significant osteopenia in adult rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!